1-    American Academy of Ophthalmology. Preferred Practice Pattern. Primary Open Angle Glaucoma 2010; 1-49

2-    American Academy of Ophthalmology. Preferred Practice Pattern. Primary Open Angle Suspect 2010; 1-28

3-    Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-713; discussion 829-830

4-    Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I. Results of the European Glaucoma Prevention Study. Ophthalmology 2005; 112: 366-375

5-    Heijl A, Leskes MC, Bengtsson B, et al. Early Manifest Glaucoma Trial Group. Redution of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-1279

6-    Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126: 487-497

7-    Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.  Arch Ophthalmol 2002; 120: 714-720; discussion 829-30

8-    Miglior S, Pfeiffer N, Torri V, Zeyen T, Cunha-Vaz J, Adamsons I. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study.  Ophthalmology 2007; 114: 3-9 

9-    Nemesure B, Wu SY, Hennis A, Leske MC. Corneal thickness and intraocular pressure in the Barbados eye studies. Arch Ophthalmol 2003; 121: 240-244

10- Heijl A, Bengsston B, Hyman L, Leske MC. Natural history of open-angle glaucoma. Ophthalmology 2009; 116: 2271-2276

11- Medeiros FA, Alencar LM, Zangwill LM, BoWd C, Sample PA, Weinreb RN. Prediction of functional loss in glaucoma from progressive optic disc damage.   Arch Ophthalmol 2009; 127: 1250-1256

12- Chauhan BC, Nicolela MT, Artes PH. Incidence and Rates of Visual Field Progression after Longitudinally Measured Optic Disc Change in Glaucoma. Ophthalmology 2009; 116: 2110-2118

13- Hood DC, Kardon RH. A framework for comparing structural and functional measures of glaucoma damage. Pro Retin Eye Res 2007; 26: 688-710

14- Medeiros FA, Vizzeri G, Zangwill LM, Alencar LM, Sample PA, Weinreb RN. Comparison of retinal nerve fiber layer and optic disc imaging for diagnosing glaucoma in patients suspected of having the disease. Ophthalmology 2008; 115: 1340-1346

15- Medeiros FA, Alencar LM, Zangwill LM, Sample PA, Weinreb RN. The relationship between intraocular pressure and progressive retinal nerve fiber layer loss in glaucoma. Ophthalmology 2009; 116: 1125-1133

16- Xin D, Greenstein VC, Ritch R, Liebmann JM, De Moraes CG, Hood DC. A comparison of functional and structural measures for identifying progression of glaucoma. Invest ophthalmol Vis  Sci 2011; 52: 519-526

17- Jampel H. Target IOP in clinical practice. In: Weinreb RN, Brandt JD, Garqay-Heath D, Medeiros FA. Intraocular Pressure. Kugler Publications, Amesterdam 2007; pp121-125

18- Singh K, Shrivastava A. Early aggressive intraocular pressure lowering, target intraocular pressure, and a novel concept for glaucoma care. Surv Ophthalmol 2008; 53, Sup 1: S33-38

19- Broman AT, Quigley HA, West SK, et al. Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data. Invest Ophthalmol Vis Sci 2008; 49: 66-76

20- Leske MC, Heijl A, Hussein M, et al. Early Manifest Glaucoma Trial Group: Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121: 48-56

21- AGIS Investigators, “The Advanced Glaucoma Intervention Study(AGIS):7.The relationship between control of intraocular pressure and visual field deterioration,” American Journal of Ophthalmology, 2000, vol.130,no.4,pp.429–440

22- South East Asia Glaucoma Interest Group: Asia Pacific Glaucoma Guidelines: Assessment: Risk Categories and treatment targets. 2^nd ed. Hong Kong: Scientific Communications International 2008. (Available at www.seagig.org)

23- Harasymowycz P, Birt C, Gooi P, et al. Medical Management of Glaucoma in the 21st Century from a Canadian Perspective. Journal of Ophthalmology, 2016, vol. 2016, Article ID 6509809, 22 pages. doi:10.1155/2016/6509809

24- European Glaucoma Society, Terminology and Guidelines for Glaucoma, 4^th edition, 2015, http://www.eugs.org/eng/EGS guide-lines4.asp.

25- Chauhan BC, Garway-Heath DF, Goni FJ et al., Practical recommendations for measuring rates of visual field changein glaucoma, British Journal of Ophthalmology, 2008, vol.92, no.4, pp. 569–573.

26- Vianna JR and Chauhan BC,How to detect progression in glaucoma, Progressin Brain Research, 2015, vol.221, pp.135–158.

27- Parikh RS, Parikh SR, Navin S et al. Practical approach to medical management of glaucoma. Indian journal of ophthalmology. 2008, 56. 223-30. 10.4103/0301-4738.40362.

28- Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye, Canadian Journal of Ophthalmology, 2009, vol.44, supplement 1, pp.S7–S93.

29- Cheema A, Chang RT, Shrivastava A et al. Update on the Medical Treatment of Primary Open-Angle Glaucoma. Asia-Pacific Journal of Ophthalmology, 2016 5(1), 51-58. DOI: 10.1097/APO.0000000000000181

30- American Academy of Ophthalmology. Glaucoma, Basic and Clinical Science Course, 2014-2015 San Francisco, Section 10, pp.161-173

31- Garway-Heath DF ,Crabb DP, Bunceetal C, Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial, The Lancet, 2015, vol. 385, no. 9975, pp. 1295–1304

32- Quaranta L, Riva I., Katsanos A. et al. Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure, Clinical Ophthalmology 2015,vol.9,pp.633–643.

33- Marquis, R. E., Whitson, J. T. Management of glaucoma: focus on pharmacological therapy. Drugs Aging. 2005, 22(1):1–21

34- Coakes RL; Brubaker RF. The Mechanism of Timolol in Lowering Intraocular Pressure In the Normal Eye. Arch Ophthalmol. 1978;96(11):2045-2048.

35- Ericson LA, “Twenty-four hourly variations of the aqueous flow. Examinations with peri limbal suction cup, Acta Ophthalmologica, 1958, vol.37, supplement50, pp.1–95.

36- Drance SM The significance of the diurnal tension variations in normal and glaucomatous eyes, Archives of Ophthalmology, 1960, vol.64,pp.494–501.

37- Lama PJ “Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment,” American Journal of Ophthalmology, 2002, vol.134, no.5, pp.749–760.

38- Salpeter ST, Ormiston , Salpeter E, Cardio selective beta- blockers for chronic obstructive pulmonary disease, Cochrane Database of Systematic Reviews, 2005 vol. 19, no. 4, Article ID CD003566.

39- Van der Valk R, Webers CA, Schouten JS et al. Intraocular pressure- lowering effects of all commonly used glaucoma drugs: a meta- analysis of randomized clinical trials. Ophthalmology 2005,vol.112, no.7,pp.1177–1185.

40- De Moraes CG, Liebmann JM, Greenfield DS, et al. Low-pressure Glaucoma Treatment Study Group. Risk factors for visual field progression in the low-pressure glaucoma treatment study. Am J Ophthalmol. 2012;154:702–11.

41- Fudemberg SF, Batiste C, and Katz LJ, Efficacy, safety, and current applications of brimonidine, Expert Opinion on Drug Safety, 2008, vol.7,no.6,pp.795–799.

42- National Institute for Health and Care Excellence, NICE guidelines [CG85]: Glaucoma: diagnosis and management, https://www.nice.org.uk/guidance/cg85

43- Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol 2008 Nov; 53 Suppl. 1: S57-68

44- Olthoff CM, Schouten JS, Van de Borne BW, et al. Non- compliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 2005 Jun; 112 (6): 953-61

45- Stewart WC, Konstas AG, Pfeiffer N. Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. J Ocul Pharmacol Ther 2004 Dec; 20 (6): 461-9

46- Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005 May; 112 (5): 863-8

47- Higginbotham EJ, Hansen J, Davis EJ, et al. Glaucoma medication persistence with a fixed combination versus multiple bottles. Curr Med Res Opin 2009 Oct; 25 (10): 2543-7

48- Schwartz GF, Pate VD, Burk C, et al. Patient persistency with topical glaucoma therapy is higher with fixed dose brimonidine/timolol than with two-bottle combinations [abstract no. 185; plus poster A408]. Association for Research in Vision and Ophthalmology; 2010 May 2-6; Fort Lauderdale (FL)

49- Rylander NR, Vold SD. Cost analysis of glaucoma medications. Am J Ophthalmol 2008 Jan; 145 (1): 106-13

50- Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol 2012 Jan- Feb; 22 (1): 5-18

51- Aptel F, Chiquet C, Romanet JP. Intraocular Pressure-Lowering Combination Therapies with Prostaglandin Analogues. Drugs, July 2012, Volume 72, Issue 10, pp 1355–1371

52- Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies, Expert Opinion on Pharmacotherapy 2007, 8:18, 3237-3249, DOI: 10.1517/14656566.8.18.3237

53- Jaenen N, Baudouin C,Pouliquen P et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications, European Journal of Ophthalmology, 2007, vol.17, no.3, pp.341–349

54- Doozandehand A, Yazdani S, Neuroprotection  in glaucoma,” Journal of Ophthalmic and Vision Research, 2016, vol. 11, no. 2, pp. 209–220.

55- Schehlein EM, Novack GD, & Robin AL. New classes of glaucoma medications. Current Opinion in Ophthalmology, 2017, 28(2), 161-168. DOI: 10.1097/ICU.0000000000000346

56- Wang RF, Williamson JE, Kopczynski et al. Effect of 0,04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics ir normotensive monkeys eys. J Glaucoma 2015; 24:51-54.

57- Bacharach J, Dubiner HB, Levy B et al. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology 2015; 122:302-307

58- Katz JL, Weiss MJ, Heah T. et al. Two phase 3 studies of the efficacy and safety of AR-13324 Ophthalmic Solution 0,02%: in patients with open angle glaucoma and ocular hypertension. Seattle, WA: Paper session presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO; 2016

59- Lewis RA, Levy B; Ramirez N, et al. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol 2016; 100:1016

60- Rasmussen CA, Kaufman PL, Ritch R et al. Latrunculin B reduces intraocular pressure in human ocular hypertension and primary open- angle glaucoma, Translational Vision Science & Technology 2014, vol. 3, no.5, article1

61- Lewis R, Christie WC, Day DG et al. Bimatoprost sustained-release implants for glaucoma therapy: interim results from a 24-month phase 1/2 clinical trial. Investigative Ophthalmology & Visual Science September 2016:57(12)

62- Perera SA, Ting DSW, Nongpiur ME et al Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population. Clinical Ophthalmology 2016:10; 757–764

63- Brandt JD, Sall K, DuBiner H et al Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert. Opthalmology 2016 123(8):1685–1694

64- Allergan Inc. Lumigan (bimatoprost ophthalmic solution) 0.01%. Full prescribing information. n.d. http://www.allergan.com/assets/pdf/lumigan_pi.pd